Market capitalization | $108.46m |
Enterprise Value | $102.87m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.06 |
P/S ratio (TTM) P/S ratio | 3.22 |
P/B ratio (TTM) P/B ratio | 6.45 |
Revenue growth (TTM) Revenue growth | 17.98% |
Revenue (TTM) Revenue | $33.65m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
5 Analysts have issued a Repro-Med Systems, Inc. forecast:
5 Analysts have issued a Repro-Med Systems, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 34 34 |
18%
18%
|
|
Gross Profit | 20 20 |
29%
29%
|
|
EBITDA | -5.56 -5.56 |
41%
41%
|
EBIT (Operating Income) EBIT | -6.45 -6.45 |
37%
37%
|
Net Profit | -6.07 -6.07 |
56%
56%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Repro-Med Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Chester, NY.
Head office | United States |
CEO | Linda Tharby |
Employees | 80 |
Founded | 1980 |
Website | www.korumedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.